

Contents

Introductory note and acknowledgements	5
Introduction	7
Drug-related economic evaluation: key issues	9
Efficiency	9
Addressing efficiency through economic evaluation	9
Perspectives in economic evaluation	9
Cost studies	9
A particular perspective on costing: public expenditure	9
Drug-related public expenditure in Europe	11
Labelled expenditure	11
Non-labelled expenditure	19
Total drug-related expenditure in Europe	21
Conclusions and recommendations	23
Limitations of the study and future developments	23
The flip side of drug-related public expenditure	24
References	26
Glossary	27